Chris Ryan

Lutetium Lu 177 vipivotide tetraxetan significantly enhances survival in metastatic hormone-sensitive prostate cancer when combined with standard therapies, according to recent trial results.

Atezolizumab significantly enhances disease-free and overall survival in ctDNA-positive muscle-invasive bladder cancer patients, reshaping treatment strategies.

New trial data reveals T-DXd plus THP significantly improves pathologic complete response rates in high-risk HER2-positive early breast cancer patients.

Pimicotinib shows promising long-term efficacy in treating tenosynovial giant cell tumor, achieving high response rates and durable outcomes in patients.

Combination therapy of osimertinib and chemotherapy significantly enhances overall survival in patients with EGFR-mutated advanced lung cancer, surpassing monotherapy outcomes.

Daratumumab-based regimens show significant clinical benefits for newly diagnosed, transplant-ineligible multiple myeloma patients, regardless of frailty changes.

Trifluridine/tipiracil shows potential in improving disease-free survival in colorectal cancer patients post-surgery, despite safety concerns.

New CAR T-cell therapy shows remarkable efficacy in treating relapsed multiple myeloma, achieving high response rates and minimal residual disease negativity.

Combination therapy with savolitinib and osimertinib shows promising results in treating advanced NSCLC with EGFR mutations and MET overexpression.

The ELEVATE trial found combining elacestrant with everolimus or ribociclib is safe and effective for ER+/HER2- metastatic breast cancer.

Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ovarian cancer, warranting further study.

DeLLphi-304 trial results showed tarlatamab significantly improved PFS and OS over chemotherapy in second-line SCLC, establishing it as a new standard.

Durvalumab plus FLOT improved event-free survival vs placebo in resectable gastric/GEJ cancer.

The BREAKWATER trial showed encorafenib, cetuximab, & mFOLFOX6 significantly improved PFS and OS in first-line BRAF V600E-mutant mCRC.

In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with low to medium FRα expression.

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, including TKD and non-TKD mutations.

TAR-200 showed durable disease-free survival in high-risk, BCG-unresponsive papillary NMIBC in SunRISe-1, with high 6/9-month DFS rates and a low cystectomy rate.

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer.

Zamtocabtagene autoleucel induced responses, including durable complete responses, in relapsed/refractory diffuse large B-cell lymphoma.

Obecabtagene autoleucel improved outcomes in relapsed/refractory B-cell acute lymphoblastic leukemia with low-risk CAR-HEMATOTOX scores in the 1/2 FELIX trial.

Encorafenib, cetuximab, and mFOLFOX6 improved ORR over mFOLFOX6 alone in BRAF V600E-mutant mCRC in the BREAKWATER trial.

Encorafenib, cetuximab, and mFOLFOX6 improved overall response rate over mFOLFOX6 alone in BRAF V600E-mutant mCRC, per BREAKWATER data.

Sintilimab plus neoadjuvant CRT improved pathological complete response rates in resectable, locally advanced ESCC, per phase 3 SCIENCE trial.

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma.

Vusolimogene oderparepvec plus nivolumab showed responses and a favorable safety profile in advanced melanoma post-anti–PD-1 therapy, per phase 2 IGNYTE trial data.

The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.

Outpatient lymphodepletion before brexucabtagene autoleucel was safe and showed similar non-relapse mortality compared with inpatient administration in B-ALL and MCL.

Aumolertinib improved progression-free survival vs placebo in patients with unresectable stage III non–small cell lung cancer, according to data from an interim analysis of the phase 3 POLESTAR trial.

The application is supported by results from the phase III DESTINY-Breast06 trial.

Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, offering a promising approach to deeper disease response.